In this special feature for our series on SGLT2 inhibitors, we are extremely pleased to present this comprehensive slide series from the WorldWIDE Initiative for Diabetes Education. In this subset of their series, the Role of the Kidneys is examined and the effects of SGLT2 inhibitors is explained….
Read More »Surprising Trends in the Use of Antidiabetic Drugs
Researchers track data on antidiabetic prescriptions dispensed from retail pharmacies in the US and note some interesting prescribing patterns. What is the most antidiabetic drug dispensed?… See more SGLT-2 Resources Despite the ability of nonpharmacological methods such as lifestyle interventions and bariatric surgery to improve type 2 diabetes outcomes, most …
Read More »John Anderson, MD, ADA Board of Directors, Introduction
John Anderson, MD, gives us a brief introduction to himself and talks about how, as an internal medicine specialist, he deals with a whole range of issues related to diabetes which he see in his patients. More videos with John Anderson, MD: Thoughts on SGLT-2 Inhibitors What is the ADA …
Read More »John Anderson, MD, Q3: What is the ADA doing about prevention of diabetes and prediabetes?
John Anderson, MD, talks about the efforts of the American Diabetes Association, and how they are using the successful experiences they have gained through landmark studies such as the Diabetes Prevention Program (DPP), applying this knowledge to new initiatives such as outreach into the community through the YMCA and other …
Read More »John Anderson, MD, Q4: At what A1c should we start to treat diabetes?
John Anderson, MD, talks about how clinicians should look at more than just a specific A1c number when beginning treatment for diabetes explaining that the measure is really only a way to project future risk. Factors such as family history, ethnic background and other characteristics may be more relevant. But …
Read More »John Anderson, MD, Q2: Thoughts on SGLT-2 Inhibitors
John Anderson, MD, talks about the new SGLT-2 inhibitors, what he has heard so far on their efficacy, and some of the concerns that have been raised about this new class of drugs…. See more SGLT-2 Resources More videos with John Anderson, MD: John Anderson, MD, ADA Board of Directors, …
Read More »Obesity 2014, Part 7
Dr. Stanley Schwartz finishes up his slides series on the current state of the obesity epidemic and its relationship with diabetes. Topics covered in this set include a discussion of the newest drug therapies on the market including the incretins and the SGLT-2 inhibitors…. To download in PowerPoint (.ppt) format: Obesity …
Read More »FDA Puts Empagliflozin on Hold
Quality issues in the manufacturing plant prevents final approval…. The investigational type 2 diabetes drug empagliflozin won’t win the FDA’s approval until “previously observed deficiencies” at a manufacturing plant are fixed, the drug’s sponsors said last week. Eli Lilly and Boehringer Ingelheim said the FDA had issued a complete response …
Read More »Vast Array of New Diabetes-Related Medications Under Development
Trade group announces 180 diabetes medicines currently in development…. The Pharmaceutical Research and Manufacturers of America (PhRMA) has announced that biopharmaceutical research companies are currently developing 180 new medicines aimed to help those affected by diabetes. Of these drugs in development, 128 of them are indicated for diabetes and 52 …
Read More »SGLT2 Inhibitors for Treatment of Type 2 Diabetes
In this special Homerun Slides presentation, details of the CANTATA-D2 study are reviewed comparing the effects and benefits of the SGLT2 inhibitors and DPP-4 inhibitors…. To download in PowerPoint (.ppt) format: SGLT2 Inhibitors for Treatment of Type 2 Diabetes See more SGLT-2 Resources
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.